Business Wire | Oct 28, 2020 07:00AM EDT

Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020

Oct. 28, 2020

WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 28, 2020--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020.

In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 4:30 PM ET on Thursday, November 5, 2020, to discuss the Company's financial results and provide a corporate update.

The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 6048987. A webcast of the conference call will be available in the "Events and Presentations" page in the "Investors" section of the Company's website at https://investors.deciphera.com/news-events/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005056/en/

CONTACT: Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc. jrobinson@deciphera.com 781-906-1112

CONTACT: Media: David Rosen Argot Partners David.Rosen@argotpartners.com 212-600-1902